BR112012000421A2 - composições e métodos para intensificar a produção de um produto biológico. - Google Patents

composições e métodos para intensificar a produção de um produto biológico.

Info

Publication number
BR112012000421A2
BR112012000421A2 BR112012000421A BR112012000421A BR112012000421A2 BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2 BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2
Authority
BR
Brazil
Prior art keywords
enhancing
compositions
production
methods
biological product
Prior art date
Application number
BR112012000421A
Other languages
English (en)
Inventor
Rossomando Anthony
Bettencourt Brian
Kocisko David
Hinkle Greg
M Maraganore John
Manoharan Muthian
Hogan Shannon
Pollard Stuart
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of BR112012000421A2 publication Critical patent/BR112012000421A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012000421A 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico. BR112012000421A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22337009P 2009-07-06 2009-07-06
US24486809P 2009-09-22 2009-09-22
US26741909P 2009-12-07 2009-12-07
US29398010P 2010-01-11 2010-01-11
US31958910P 2010-03-31 2010-03-31
US33439810P 2010-05-13 2010-05-13
US35493210P 2010-06-15 2010-06-15
PCT/US2010/041099 WO2011005786A2 (en) 2009-07-06 2010-07-06 Compositions and methods for enhancing production of a biological product

Publications (1)

Publication Number Publication Date
BR112012000421A2 true BR112012000421A2 (pt) 2019-09-24

Family

ID=43429810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000421A BR112012000421A2 (pt) 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico.

Country Status (6)

Country Link
US (1) US20140099666A1 (pt)
EP (1) EP2451823A4 (pt)
JP (1) JP2014501097A (pt)
BR (1) BR112012000421A2 (pt)
CA (1) CA2767225A1 (pt)
WO (1) WO2011005786A2 (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
EP3296398A1 (en) * 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CN102686729B (zh) 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
US20120191434A1 (en) * 2010-08-25 2012-07-26 Gt Life Sciences, Inc. Articles of manufacture and methods for modeling chinese hamster ovary (cho) cell metabolism
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US10202643B2 (en) 2011-10-31 2019-02-12 University Of Utah Research Foundation Genetic alterations in glioma
WO2013102155A1 (en) * 2011-12-29 2013-07-04 Cell Machines, Inc. Cells for virus and protein production
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
EA201492123A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов smn
LT2922554T (lt) * 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
US9644207B2 (en) 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
SG11201607038TA (en) * 2014-03-04 2016-09-29 Sigma Aldrich Co Llc Viral resistant cells and uses thereof
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3355924A1 (en) 2015-09-29 2018-08-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of treating and preventing amyotrophic lateral sclerosis
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US20190142860A1 (en) * 2015-10-14 2019-05-16 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11710048B2 (en) 2016-07-05 2023-07-25 Samsung Electronics Co., Ltd. Method and device for assessing feasibility of biochemical reaction in organism
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
KR101837855B1 (ko) 2016-10-18 2018-03-13 단국대학교 산학협력단 뎅기바이러스 혈청형 2의 메틸트랜스퍼라제 활성을 억제하는 rna 앱타머
JP7213180B2 (ja) * 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3654860A1 (en) 2017-07-17 2020-05-27 Voyager Therapeutics, Inc. Trajectory array guide system
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
WO2019115417A2 (en) * 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
CN116375774A (zh) 2017-12-29 2023-07-04 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
WO2019197845A1 (en) * 2018-04-12 2019-10-17 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3818161A1 (en) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
WO2020007702A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3877408A4 (en) * 2018-11-06 2022-08-24 University of Miami COMPOSITIONS AND PRODUCTION OF RECOMBINANT AAV VIRUS VECTORS CAPABLE OF IN VIVO GLYCOENGINEERING
TW202039858A (zh) 2019-01-18 2020-11-01 美商航海家醫療公司 用於生產aav顆粒之方法及系統
CN109852648B (zh) * 2019-04-11 2022-08-09 广西大学 酶法制备右旋糖酐硒聚物的方法
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
CN110117607A (zh) * 2019-04-29 2019-08-13 贵州大学 一种玉米黑粉菌效应蛋白Pit2基因的重组载体和表达方法
WO2020225301A1 (en) * 2019-05-07 2020-11-12 Universität Bern Nucleic acids for inhibiting expression of pros1 in a cell
AU2020274339C1 (en) 2019-05-13 2023-08-31 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220364114A1 (en) 2019-08-26 2022-11-17 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022032282A1 (en) * 2020-08-06 2022-02-10 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Methods and reagents for microbiome analysis
US20230313187A1 (en) * 2020-09-04 2023-10-05 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products
IT202000023647A1 (it) * 2020-10-07 2022-04-07 Univ Degli Studi Padova Sirna nel trattamento della sindrome ectrodattilia-displasia ectodermica-palatoschisi (eec)
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4326855A1 (en) * 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
WO2022256519A1 (en) * 2021-06-02 2022-12-08 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023111335A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Oligonucleotides capable of increasing glucocerebrosidase expression
CN114317511B (zh) * 2022-03-10 2022-06-14 北京爱普益医学检验中心有限公司 蛋白、基因、重组载体、表达盒、宿主及用途
WO2023194586A2 (en) * 2022-04-08 2023-10-12 Secarna Pharmaceuticals Gmbh & Co. Kg Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases
GB202208022D0 (en) * 2022-05-31 2022-07-13 Sisaf Ltd Therapeutic compounds and compositions
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN117344061B (zh) * 2023-12-05 2024-02-27 云南省细胞质量检测评价中心有限公司 一种同时检测五种人源病毒ebv、hbv、hcv、hiv、hpv的方法、试剂盒、引物和探针及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
WO2002072762A2 (en) * 2001-03-08 2002-09-19 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
KR100434118B1 (ko) * 2001-09-17 2004-06-04 한국과학기술원 카스파제-3에 대한 안티센스 뉴클레오타이드, 그의발현벡터 및 이를 이용한 세포예정사의 억제방법
US20090023670A1 (en) * 2006-05-19 2009-01-22 Sebestyen Magdolna G Regulation of Transgene Expression by RNA Interference
MX2009004170A (es) * 2006-10-24 2009-06-26 Trubion Pharmaceuticals Inc Materiales y metodos para inmunoglicoproteinas mejoradas.
WO2009012173A2 (en) * 2007-07-13 2009-01-22 Dharmacon, Inc. Enhanced biotherapeutic production using inhibitory rna

Also Published As

Publication number Publication date
WO2011005786A2 (en) 2011-01-13
WO2011005786A3 (en) 2011-03-24
CA2767225A1 (en) 2011-01-13
EP2451823A4 (en) 2013-07-03
EP2451823A2 (en) 2012-05-16
JP2014501097A (ja) 2014-01-20
US20140099666A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
BR112012000421A2 (pt) composições e métodos para intensificar a produção de um produto biológico.
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI1010581A2 (pt) micro-organismos para a produção de 1,4-butanodiol e métodos relacionados
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
BRPI1013822A2 (pt) Método para síntese de um trissacarídeo.
BRPI0925037A2 (pt) Composição contendo piceatanol e método de produzir a composição contendo piceatanol.
BRPI0908130A2 (pt) Produto
BRPI1012875A2 (pt) composições farmacêuticas sólidas e processos para sua produção
IT1393352B1 (it) Apparato di aliquotazione di contenitori di materiale biologico.
BRPI1011338A2 (pt) material de produção de embalagem
BRPI0913232A2 (pt) Produto alimentício
FI20085767L (fi) Kipsituote
BRPI1014090A2 (pt) produto de bebida instantânea
GB0904214D0 (en) Biological products
FI20095500A0 (fi) Tuote ja menetelmä sen valmistamiseksi
BRPI1010735A2 (pt) composição para a produção de um fungicida e um bactericida biológico
FI20095144A0 (fi) Elintarvikevalmiste
GB0900425D0 (en) Biological products
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
FR2944023B1 (fr) Procede de preparation de superplastifiants.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
BR112012002613A2 (pt) processo para a preparação de cloro.
FI20086024A0 (fi) Uusi farmaseuttinen tuote
BR112012001503A2 (pt) Processo para preparação de nebivopol.
BRPI0920277A2 (pt) produto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.